- Home
- SST vs CALC Comparison
SST vs CALC Comparison
Compare SST & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- CALC
- Stock Information
- Founded
- SST 2013
- CALC 2011
- Country
- SST United States
- CALC United States
- Employees
- SST N/A
- CALC N/A
- Industry
- SST Diversified Commercial Services
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- CALC Health Care
- Exchange
- SST Nasdaq
- CALC Nasdaq
- Market Cap
- SST 57.3M
- CALC 48.1M
- IPO Year
- SST N/A
- CALC N/A
- Fundamental
- Price
- SST $8.87
- CALC $2.85
- Analyst Decision
- SST Strong Buy
- CALC Strong Buy
- Analyst Count
- SST 1
- CALC 2
- Target Price
- SST $10.00
- CALC $14.50
- AVG Volume (30 Days)
- SST 51.3K
- CALC 63.4K
- Earning Date
- SST 11-06-2025
- CALC 11-12-2025
- Dividend Yield
- SST N/A
- CALC N/A
- EPS Growth
- SST N/A
- CALC N/A
- EPS
- SST N/A
- CALC N/A
- Revenue
- SST $317,055,000.00
- CALC N/A
- Revenue This Year
- SST N/A
- CALC N/A
- Revenue Next Year
- SST $12.20
- CALC N/A
- P/E Ratio
- SST N/A
- CALC N/A
- Revenue Growth
- SST N/A
- CALC N/A
- 52 Week Low
- SST $2.90
- CALC $1.42
- 52 Week High
- SST $15.00
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- SST 68.38
- CALC 46.04
- Support Level
- SST $7.51
- CALC $3.00
- Resistance Level
- SST $7.90
- CALC $3.73
- Average True Range (ATR)
- SST 0.64
- CALC 0.35
- MACD
- SST 0.15
- CALC -0.00
- Stochastic Oscillator
- SST 94.33
- CALC 20.72
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.